Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 1
1975 1
1976 7
1977 11
1978 12
1979 30
1980 24
1981 41
1982 58
1983 50
1984 67
1985 68
1986 58
1987 74
1988 83
1989 82
1990 80
1991 84
1992 82
1993 102
1994 107
1995 76
1996 87
1997 99
1998 93
1999 92
2000 122
2001 126
2002 130
2003 176
2004 160
2005 202
2006 266
2007 266
2008 268
2009 266
2010 300
2011 355
2012 371
2013 410
2014 455
2015 454
2016 437
2017 524
2018 553
2019 740
2020 863
2021 976
2022 1086
2023 979
2024 796
2025 1

Text availability

Article attribute

Article type

Publication date

Search Results

11,429 results

Results by year

Filters applied: . Clear all
Page 1
Buprenorphine Treatment for Opioid Use Disorder: An Overview.
Shulman M, Wai JM, Nunes EV. Shulman M, et al. CNS Drugs. 2019 Jun;33(6):567-580. doi: 10.1007/s40263-019-00637-z. CNS Drugs. 2019. PMID: 31062259 Free PMC article. Review.
There are currently three World Health Organization-recommended and US Food and Drug Administration-approved medication treatments for opioid use disorder: the full opioid agonist methadone, the opioid partial agonist buprenorphine, and the opioid receptor antagonist naltr …
There are currently three World Health Organization-recommended and US Food and Drug Administration-approved medication treatments for opioi …
Microinduction of Buprenorphine/Naloxone: A Review of the Literature.
Ahmed S, Bhivandkar S, Lonergan BB, Suzuki J. Ahmed S, et al. Am J Addict. 2021 Jul;30(4):305-315. doi: 10.1111/ajad.13135. Epub 2020 Dec 30. Am J Addict. 2021. PMID: 33378137 Review.
BACKGROUND AND OBJECTIVES: Buprenorphine's high-binding affinity as a partial -opioid agonist displaces preexisting full agonists causing precipitated withdrawal, which requires most individuals starting buprenorphine to endure moderate withdrawal prior to in …
BACKGROUND AND OBJECTIVES: Buprenorphine's high-binding affinity as a partial -opioid agonist displaces preexisting full agoni …
Understanding Buprenorphine for Use in Chronic Pain: Expert Opinion.
Webster L, Gudin J, Raffa RB, Kuchera J, Rauck R, Fudin J, Adler J, Mallick-Searle T. Webster L, et al. Pain Med. 2020 Apr 1;21(4):714-723. doi: 10.1093/pm/pnz356. Pain Med. 2020. PMID: 31917418 Free PMC article. Review.
METHODS: The consensus panel met on March 25, 2019, to discuss relevant literature and provide recommendations on interpreting buprenorphine as a partial -opioid receptor agonist, prescribing buprenorphine before some Schedule II, III, or IV options, perioperative/t …
METHODS: The consensus panel met on March 25, 2019, to discuss relevant literature and provide recommendations on interpreting buprenorph …
Evidence on Buprenorphine Dose Limits: A Review.
Grande LA, Cundiff D, Greenwald MK, Murray M, Wright TE, Martin SA. Grande LA, et al. J Addict Med. 2023 Sep-Oct 01;17(5):509-516. doi: 10.1097/ADM.0000000000001189. Epub 2023 Jun 16. J Addict Med. 2023. PMID: 37788601 Free PMC article. Review.
METHODS: This review discusses patient-centered goals and clinical criteria for determining dose adequacy, reviews the history of buprenorphine dose regulation in the United States, examines pharmacological and clinical research results with buprenorphine doses up t …
METHODS: This review discusses patient-centered goals and clinical criteria for determining dose adequacy, reviews the history of bupreno …
Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence.
Elkader A, Sproule B. Elkader A, et al. Clin Pharmacokinet. 2005;44(7):661-80. doi: 10.2165/00003088-200544070-00001. Clin Pharmacokinet. 2005. PMID: 15966752 Review.
Most of a dose of buprenorphine is eliminated in the faeces, with approximately 10-30% excreted in urine. Naloxone has been added to a sublingual formulation of buprenorphine to reduce the abuse liability of the product. The presence of naloxone does not appear to i …
Most of a dose of buprenorphine is eliminated in the faeces, with approximately 10-30% excreted in urine. Naloxone has been added to …
Perioperative Considerations for the Patient with Opioid Use Disorder on Buprenorphine, Methadone, or Naltrexone Maintenance Therapy.
Harrison TK, Kornfeld H, Aggarwal AK, Lembke A. Harrison TK, et al. Anesthesiol Clin. 2018 Sep;36(3):345-359. doi: 10.1016/j.anclin.2018.04.002. Epub 2018 Jul 11. Anesthesiol Clin. 2018. PMID: 30092933 Review.
As part of a national effort to combat the current US opioid epidemic, use of currently Food and Drug Administration-approved drugs for the treatment of opioid use disorder/opioid addiction (buprenorphine, methadone, and naltrexone) is on the rise. To provide optimal pain …
As part of a national effort to combat the current US opioid epidemic, use of currently Food and Drug Administration-approved drugs for the …
Buprenorphine.
Lewis JW. Lewis JW. Drug Alcohol Depend. 1985 Feb;14(3-4):363-72. doi: 10.1016/0376-8716(85)90067-5. Drug Alcohol Depend. 1985. PMID: 2986930 Review.
Buprenorphine is a mixed agonist-antagonist with high affinity at both mu and kappa opiate receptors. ...Some misuse of buprenorphine has been reported in 3 of the 29 countries in which buprenorphine is marketed despite its wide clinical acceptance, particula …
Buprenorphine is a mixed agonist-antagonist with high affinity at both mu and kappa opiate receptors. ...Some misuse of buprenorph …
Buprenorphine and the Boards: Missed Opportunities.
Hayden M, Kishore S. Hayden M, et al. J Gen Intern Med. 2023 Jun;38(8):1984-1985. doi: 10.1007/s11606-023-08038-1. Epub 2023 Mar 29. J Gen Intern Med. 2023. PMID: 36988866 Free PMC article. No abstract available.
Transdermal buprenorphine.
Evans HC, Easthope SE. Evans HC, et al. Drugs. 2003;63(19):1999-2010; discussion 2011-2. doi: 10.2165/00003495-200363190-00003. Drugs. 2003. PMID: 12962515 Review.
Buprenorphine is a low molecular weight, lipophilic, opioid analgesic. Recently, a transdermal matrix patch formulation of buprenorphine has become available in three dosage strengths designed to release buprenorphine at 35, 52.5 and 70 micro g/h over a 72-ho …
Buprenorphine is a low molecular weight, lipophilic, opioid analgesic. Recently, a transdermal matrix patch formulation of bupreno …
The utilization of buprenorphine in chronic pain.
Urits I, Pham C, Swanson D, Berardino K, Bandi P, Amgalan A, Kaye RJ, Jung JW, Kaye AD, Paladini A, Varrassi G, Kaye AM, Manchikanti L, Viswanath O. Urits I, et al. Best Pract Res Clin Anaesthesiol. 2020 Sep;34(3):355-368. doi: 10.1016/j.bpa.2020.06.005. Epub 2020 Jul 3. Best Pract Res Clin Anaesthesiol. 2020. PMID: 33004153 Review.
During the past decade of the opioid epidemic, methadone was the primary treatment for opioid addiction until buprenorphine was approved. Buprenorphine's high-affinity partial agonist properties make it a good alternative to methadone due to lower abuse poten …
During the past decade of the opioid epidemic, methadone was the primary treatment for opioid addiction until buprenorphine was appro …
11,429 results
You have reached the last available page of results. Please see the User Guide for more information.